Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Bausch Health looks to Allegro to create long-term value

Bausch Health recently announced that it had entered into an agreement with Allegro to acquire an option to purchase all of the latter’s ophthalmology assets. This transaction will be a significant step for Bausch Health in its strategy to create a long-term growth opportunity, says GlobalData, a leading data and analytics company. Vinie Varkey, MSc, […]
Read more

Oral GnRH antagonists could have market potential in female health space beyond endometriosis-related pain and uterine fibroid indications

Oral GnRH antagonists have off-label potential in the female infertility space, beyond the indications of endometriosis-associated pain and uterine fibroids, which constitute the main development focus for companies competing in the space, says GlobalData, a leading data and analytics company. Due to their novel oral formulation, the company notes that GnRH antagonists could replace subcutaneous […]
Read more

Competition intensifies in SMA market with new Evrysdi two-year data

Following the news that Roche has announced new positive two-year data for Evrysdi (risdiplam) in infants with spinal muscular atrophy (SMA); Philippa Salter, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “Having been approved earlier this year, Roche’s Evrysdi now reaches the market – albeit a whole four years behind […]
Read more

PAH patients to benefit amid telemedicine regulatory changes

Following President Trump’s announced executive order directing the Department of Health and Human Services (HHS) to issue rules ensuring that specific regulatory changes to telemedicine will remain in place once the COVID-19 pandemic ends, HHS will need to healthcare access to rural areas and to create a novel value-based payment model to improve reimbursement, according […]
Read more

Bispecific antibodies will start maturing after 2021 with estimated sales in oncology of $6bn by 2025

The clinical success of Amgen’s Blincyto has amplified the intensive pace of development for bispecific antibodies in oncology. According to GlobalData’s drugs database, there are 106 bispecific antibody molecules – with various targets – currently in the pipeline. Furthermore, there are 263 ongoing/planning to enroll clinical trials involving a bispecific antibody. Sakis Paliouras, PhD, Oncology […]
Read more

Crohn’s disease set to reach 1.6 million cases in 8MM by 2029

The diagnosed prevalent cases of Crohn’s disease (CD) in the eight major markets (*8MM) are projected to increase from 1,339,543 cases in 2019 to 1,629,940 cases in 2029, equating to an annual growth rate (AGR) of 2.17%, according to GlobalData, a leading data and analytics company. The natural course of CD, with low mortality, as well […]
Read more

vTV’s Alzheimer’s and type 2 diabetes therapy has some support for positive data but skepticism remains, says GlobalData

In light of another setback in the Alzheimer’s disease (AD) drug development field, with the failure of Roche and AC Immune’s antitau antibody, all eyes will be on results for vTv Therapeutics’ azeliragon for AD and type 2 diabetes; William Newton, Pharma Writer for the Investigative News team at GlobalData, offers his view: “Although azeliragon […]
Read more

Amyotrophic lateral sclerosis set to increase to 65,900 cases in the 8MM in 2029 due to aging populations, says GlobalData

The diagnosed prevalent cases of amyotrophic lateral sclerosis (ALS) in the eight major markets (*8MM) is expected to increase from 57,800 cases in 2019 to 65,900 cases in 2029, at an annual growth rate (AGR) of 1.41%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Amyotrophic Lateral Sclerosis: Epidemiology Forecast to […]
Read more

Positive CHMP opinion on Baricitinib in atopic dermatitis positions it to take on Dupixent, says GlobalData

Eli Lilly’s baricitinib, marketed as Olumiant in rheumatoid arthritis, has received a recommendation of approval from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for moderate to severe adult atopic dermatitis (AD) patients, positioning the drug to take on Sanofi and Regeneron’s juggernaut Dupixent (dupilumab), says GlobalData, a leading data […]
Read more
1 … 80 81 82 83 84 … 110